Pralatrexate: Phase I/II data

In a dose-escalation Phase I/II trial in patients with lymphoproliferative malignancies, the maximum tolerated

Read the full 148 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE